Kalaris Therapeutics (KLRS) Competitors

$5.30 -0.23 (-4.16%)

Closing price 04:00 PM Eastern

Extended Trading

$5.30 0.00 (-0.09%)

As of 04:04 PM Eastern

KLRS vs. UPB, IMMX, ZURA, ENGN, and CTNM

Should you be buying Kalaris Therapeutics stock or one of its competitors? The main competitors of Kalaris Therapeutics include Upstream Bio (UPB), Immix Biopharma (IMMX), Zura Bio (ZURA), enGene (ENGN), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry.

How does Kalaris Therapeutics compare to Upstream Bio?

Kalaris Therapeutics (NASDAQ:KLRS) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

: Kalaris Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -5,026.03%. Upstream Bio's return on equity of -36.48% beat Kalaris Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Kalaris Therapeutics N/A -73.11% -43.56%
Upstream Bio -5,026.03% -36.48% -35.38%
: Kalaris Therapeutics presently has a consensus price target of $14.00, suggesting a potential upside of 164.15%. Upstream Bio has a consensus price target of $39.00, suggesting a potential upside of 327.63%. Given Upstream Bio's higher probable upside, analysts plainly believe Upstream Bio is more favorable than Kalaris Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kalaris Therapeutics
1 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.71
Upstream Bio
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

1 Strong Buy rating(s)
2.60
: In the previous week, Upstream Bio had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 2 mentions for Upstream Bio and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 1.93 beat Upstream Bio's score of 1.18 indicating that Kalaris Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kalaris Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Upstream Bio
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 13.6% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: Kalaris Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Comparatively, Upstream Bio has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.
: Kalaris Therapeutics has higher earnings, but lower revenue than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kalaris Therapeutics N/A N/A -$43.44M -$4.21 N/A
Upstream Bio $2.85M 174.14 -$143.44M -$2.67 N/A

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-73.11%	-43.56%
Upstream Bio	-5,026.03%	-36.48%	-35.38%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Upstream Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$4.21	N/A
Upstream Bio	$2.85M	174.14	-$143.44M	-$2.67	N/A

Summary

Kalaris Therapeutics beats Upstream Bio on 8 of the 15 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Immix Biopharma?

Kalaris Therapeutics (NASDAQ:KLRS) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

: Kalaris Therapeutics' return on equity of -73.11% beat Immix Biopharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Kalaris Therapeutics N/A -73.11% -43.56%
Immix Biopharma N/A -101.25% -73.39%
: Kalaris Therapeutics presently has a consensus price target of $14.00, suggesting a potential upside of 164.15%. Immix Biopharma has a consensus price target of $18.25, suggesting a potential upside of 90.90%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Kalaris Therapeutics is more favorable than Immix Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kalaris Therapeutics
1 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.71
Immix Biopharma
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
: In the previous week, Kalaris Therapeutics and Kalaris Therapeutics both had 1 articles in the media. Kalaris Therapeutics' average media sentiment score of 1.93 beat Immix Biopharma's score of 1.34 indicating that Kalaris Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kalaris Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Immix Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: Kalaris Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500.
: Immix Biopharma is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kalaris Therapeutics N/A N/A -$43.44M -$4.21 N/A
Immix Biopharma N/A N/A -$29.44M -$0.89 N/A

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-73.11%	-43.56%
Immix Biopharma	N/A	-101.25%	-73.39%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$4.21	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.89	N/A

Summary

Kalaris Therapeutics beats Immix Biopharma on 10 of the 12 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Zura Bio?

Kalaris Therapeutics (NASDAQ:KLRS) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

: In the previous week, Zura Bio had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 2 mentions for Zura Bio and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 1.93 beat Zura Bio's score of 0.00 indicating that Kalaris Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kalaris Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Zura Bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Kalaris Therapeutics presently has a consensus price target of $14.00, suggesting a potential upside of 164.15%. Zura Bio has a consensus price target of $10.75, suggesting a potential upside of 107.53%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Kalaris Therapeutics is more favorable than Zura Bio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kalaris Therapeutics
1 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.71
Zura Bio
1 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.67
: Zura Bio is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kalaris Therapeutics N/A N/A -$43.44M -$4.21 N/A
Zura Bio N/A N/A -$99.35M -$1.06 N/A
: 66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by insiders. Comparatively, 14.2% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Kalaris Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500.
: Zura Bio's return on equity of -59.06% beat Kalaris Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Kalaris Therapeutics N/A -73.11% -43.56%
Zura Bio N/A -59.06% -48.04%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$4.21	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.06	N/A

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-73.11%	-43.56%
Zura Bio	N/A	-59.06%	-48.04%

Summary

Kalaris Therapeutics beats Zura Bio on 10 of the 13 factors compared between the two stocks.

How does Kalaris Therapeutics compare to enGene?

enGene (NASDAQ:ENGN) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

: enGene currently has a consensus target price of $22.69, indicating a potential upside of 187.55%. Kalaris Therapeutics has a consensus target price of $14.00, indicating a potential upside of 164.15%. Given enGene's stronger consensus rating and higher possible upside, equities analysts clearly believe enGene is more favorable than Kalaris Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
enGene
1 Sell rating(s)
1 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.82
Kalaris Therapeutics
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.71
: In the previous week, enGene had 7 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 8 mentions for enGene and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 1.93 beat enGene's score of 0.57 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
enGene
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Kalaris Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
: enGene's return on equity of -55.83% beat Kalaris Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
enGene N/A -55.83% -45.74%
Kalaris Therapeutics N/A -73.11% -43.56%
: 64.2% of enGene shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 10.4% of enGene shares are owned by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: enGene is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
enGene N/A N/A -$117.30M -$2.25 N/A
Kalaris Therapeutics N/A N/A -$43.44M -$4.21 N/A
: enGene has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Kalaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.83%	-45.74%
Kalaris Therapeutics	N/A	-73.11%	-43.56%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.25	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$4.21	N/A

Summary

Kalaris Therapeutics beats enGene on 7 of the 13 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

: In the previous week, Contineum Therapeutics had 5 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 6 mentions for Contineum Therapeutics and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 1.93 beat Contineum Therapeutics' score of 0.38 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Contineum Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kalaris Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
: Contineum Therapeutics currently has a consensus target price of $19.50, indicating a potential upside of 35.51%. Kalaris Therapeutics has a consensus target price of $14.00, indicating a potential upside of 164.15%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than Contineum Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Contineum Therapeutics
1 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
Kalaris Therapeutics
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.71
: Contineum Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Contineum Therapeutics N/A N/A -$59.98M -$2.18 N/A
Kalaris Therapeutics N/A N/A -$43.44M -$4.21 N/A
: Contineum Therapeutics' return on equity of -30.08% beat Kalaris Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Contineum Therapeutics N/A -30.08% -28.27%
Kalaris Therapeutics N/A -73.11% -43.56%
: Contineum Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.
: 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 11.3% of Contineum Therapeutics shares are owned by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kalaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	N/A	N/A	-$59.98M	-$2.18	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$4.21	N/A

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-30.08%	-28.27%
Kalaris Therapeutics	N/A	-73.11%	-43.56%

Summary

Kalaris Therapeutics beats Contineum Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Kalaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRS vs. The Competition

Export

Metric	Kalaris Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$121.85M	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-1.26	38.85	29.04	28.47
Price / Sales	N/A	155.51	476.61	60.92
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	1.26	7.03	9.67	6.67
Net Income	-$43.44M	$23.62M	$3.55B	$332.53M
7 Day Performance	-6.03%	3.68%	1.70%	2.01%
1 Month Performance	-8.46%	7.16%	5.62%	9.19%
1 Year Performance	N/A	67.05%	34.41%	39.59%

Kalaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRS Kalaris Therapeutics	3.5093 of 5 stars	$5.30 -4.2%	$14.00 +164.2%	N/A	$121.85M	N/A	N/A	110	Positive News
UPB Upstream Bio	1.8661 of 5 stars	$9.32 +1.5%	$39.00 +318.7%	N/A	$506.92M	$2.85M	N/A	38	Positive News
IMMX Immix Biopharma	2.9808 of 5 stars	$9.33 +4.4%	$18.25 +95.7%	N/A	$494.39M	N/A	N/A	9	Positive News
ZURA Zura Bio	2.4012 of 5 stars	$5.20 +2.4%	$10.75 +106.7%	N/A	$493.38M	N/A	N/A	3	Upcoming Earnings
ENGN enGene	3.0588 of 5 stars	$7.34 +0.9%	$22.69 +209.1%	N/A	$491.57M	N/A	N/A	31

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRS) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. UPB, IMMX, ZURA, ENGN, and CTNM

How does Kalaris Therapeutics compare to Upstream Bio?

Summary

How does Kalaris Therapeutics compare to Immix Biopharma?

Summary

How does Kalaris Therapeutics compare to Zura Bio?

Summary

How does Kalaris Therapeutics compare to enGene?

Summary

How does Kalaris Therapeutics compare to Contineum Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. UPB, IMMX, ZURA, ENGN, and CTNM

How does Kalaris Therapeutics compare to Upstream Bio?

Summary

How does Kalaris Therapeutics compare to Immix Biopharma?

Summary

How does Kalaris Therapeutics compare to Zura Bio?

Summary

How does Kalaris Therapeutics compare to enGene?

Summary

How does Kalaris Therapeutics compare to Contineum Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools